In a multicenter cohort, physicians modified surveillance intervals in 55% of Barrett's esophagus patients after TissueCypher testing and aligned recommendations with molecular risk classification in 79% of cases. Among intermediate/high-risk patients, 93% received shorter surveillance intervals, and 92% of non-dysplastic cases were escalated compared with traditional guidelines.

When compared with the Progression in Barrett's Esophagus (PIB) model, TissueCypher classified 84% of patients as low risk versus 38% by PIB, yielding a kappa concordance of 0.04. Most discordance arose from patients deemed intermediate/high risk by PIB but low risk by molecular analysis, highlighting gaps in traditional histopathological assessment.

The data suggest molecular stratification can drive risk-aligned management, enabling escalation of care through endoscopic eradication therapy or shortened surveillance for higher-risk patients and de-escalation for lower-risk individuals. Such personalized approaches may optimize healthcare resources and improve patient outcomes by targeting interventions more effectively.

TissueCypher is an AI-driven spatialomics test that predicts a patient’s five-year risk of progression to high-grade dysplasia or esophageal adenocarcinoma based on molecular signatures in standard endoscopic biopsy samples. Validated in biopsies from over 8,000 patients and supported by 17 peer-reviewed studies, the test integrates into routine practice without additional procedures.